Enjoy complimentary customisation on priority with our Enterprise License!
The cerebral palsy market share is expected to increase by USD 961.91 million from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 5.45%.
This cerebral palsy market research report provides valuable insights on the post-COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers cerebral palsy market segmentation by product (anticonvulsant drugs, antispastic drugs, anticholinergic drugs, NSAIDs, Antidepressants, and others) and geography (North America, Asia, Europe, and ROW). The cerebral palsy market report also offers information on several market vendors, including AbbVie Inc., Acorda Therapeutics Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, GW Pharmaceuticals Plc, Johnson and Johnson Inc., Medtronic Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. among others.
Download the Free Report Sample to Unlock the Cerebral Palsy Market Size for the Forecast Period and Other Important Statistics
The rising incidence of cerebral palsy is notably driving the cerebral palsy market growth, although factors such as complex and multifactorial etiology may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the cerebral palsy industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Cerebral Palsy Market Driver
The rising incidence of cerebral palsy is one of the key drivers supporting the cerebral palsy market share growth. Cerebral palsy is one of the most common types of motor disorders in early childhood. The incidence rate of cerebral palsy is continuously increasing worldwide. Children with a low birth weight are more likely to develop cerebral palsy. The incidence rate is three times more in resource-poor countries compared with developed nations. Meanwhile, prenatal causes are also responsible for about 70% of cerebral palsy cases. The most common prenatal cause is asphyxia neonatorum (when the baby does not get enough oxygen during birth). In most developing countries, a vast majority of the population is ignorant about the importance of prenatal care. The lack of proper prenatal care may increase the chances of children developing cerebral palsy. Thus, the rising incidence of cerebral palsy may drive market growth during the forecast period.
Key Cerebral Palsy Market Trend
The availability of advanced therapeutic modalities for cerebral palsy is another factor driving the cerebral palsy market growth. Conventional treatment options for cerebral palsy include physical therapy, occupational therapy, speech and language therapy, recreational therapy, surgery, and medications. Some technological advances have already been introduced in the market while some are in the late stage of development or in the trial stage for the treatment of cerebral palsy. They include FES, virtual reality, stem cell therapy, and robotics. For example, FES involves the stimulation of muscles using electrical impulses to produce contractions and generate movements. It has been in use for many years for the improvement of movements in patients. Thus, multiple treatment options and disease management options are available for cerebral palsy and to improve the quality of life of patients.
Key Cerebral Palsy Market Challenge
Complex and multifactorial etiology is hampering the cerebral palsy market growth. Defining one particular therapy to target the challenges of cerebral palsy is difficult as the disease has a complex etiology. Various factors contribute to cerebral palsy, including maternal- and infant-related characteristics. The disease is known to be caused by an interplay of certain events during the pre-conceptional, antepartum, intrapartum, and post-neonatal periods. Women with neurological disorders are at an increased risk of giving birth to children with cerebral palsy. Also, the presence of intrapartum fever, which occurs during labor, is a major risk factor for cerebral palsy. Multifetal gestation, placental pathology, genetic factors, birth defects, and thrombophilia are the other general etiological factors that are responsible for cerebral palsy. Thus, the prediction of the exact cause of the disease is a challenge.
This cerebral palsy market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2021-2025.
Technavio categorizes the cerebral palsy market as a part of the global pharmaceuticals market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the cerebral palsy market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the cerebral palsy market encompasses successful business strategies deployed by the key vendors. The cerebral palsy market is concentrated and the vendors are deploying growth strategies such as operational cost, innovation, competitive pricing, and improvement of product quality to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The cerebral palsy market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the cerebral palsy market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chains is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
The value chain of the pharmaceuticals market includes the following core components:
The report has further elucidated on other innovative approaches being followed by service providers to ensure a sustainable market presence.
For more insights on the market share of various regions Request for a FREE sample now!
39% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the cerebral palsy market in North America. Market growth in this region will be slower than the growth of the market in Asia.
Patients in the US are highly dependent on drug therapy for the treatment of cerebral palsy symptoms, which will facilitate the cerebral palsy market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
The COVID-19 outbreak led to a slight decline in the growth of the cerebral palsy market in North America in Q1 2020, owing to the temporary pause on the research of new drugs for cerebral palsy and reduced clinic visits because of the stay-at-home policy. This led to a decline in the sales of cerebral palsy therapeutics. However, the adoption of telehealth and the lifting of stay-at-home policies regained the market revenue in the region. In addition, fastened research programs for cerebral palsy are expected to drive the growth of the regional market during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The cerebral palsy market share growth by the anticonvulsant drugs segment will be significant during the forecast period. The use of anticonvulsants is crucial for the management of cerebral palsy. The sales of leading anticonvulsants, including NEURONTIN, Lamictal, Trileptal, TOPAMAX, and ZONEGRAN, contribute to the market size. The market size for this segment has been derived based on annual sales data as well as the incidence rate of convulsions among patients with cerebral palsy.
This report provides an accurate prediction of the contribution of all the segments to the growth of the cerebral palsy market size and actionable market insights on post COVID-19 impact on each segment.
Cerebral Palsy Drugs market - The market share is expected to grow at a CAGR of more than 5% during the 2019-2023 forecast period.
|
Cerebral Palsy Market Scope |
|
|
Report Coverage |
Details |
|
Page number |
120 |
|
Base year |
2020 |
|
Forecast period |
2021-2025 |
|
Growth momentum & CAGR |
Accelerate at a CAGR of 5.45% |
|
Market growth 2021-2025 |
$ 961.91 million |
|
Market structure |
Concentrated |
|
YoY growth (%) |
4.89 |
|
Regional analysis |
North America, Asia, Europe, and ROW |
|
Performing market contribution |
North America at 39% |
|
Key consumer countries |
US, Canada, Australia, China, and UK |
|
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
|
Key companies profiled |
AbbVie Inc., Acorda Therapeutics Inc., Eli Lilly and Co., F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, GW Pharmaceuticals Plc, Johnson and Johnson Inc., Medtronic Plc, Pfizer Inc., and Teva Pharmaceutical Industries Ltd. |
|
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period |
|
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
***1. Executive Summary
**1.1 Market Overview
*Exhibit 01: Key Finding 1
*Exhibit 02: Key Finding 2
*Exhibit 03: Key Finding 3
*Exhibit 04: Key Finding 5
*Exhibit 05: Key Finding 6
*Exhibit 06: Key Finding 7
*Exhibit 07: Key Finding 8
***2. Market Landscape
**2.1 Market ecosystem
*2.1.1 Parent Market
*Exhibit 08: Parent market
*Exhibit 09: Market characteristics
**2.2 Value chain analysis
*Exhibit 10: Value chain analysis: Pharmaceuticals
*2.2.1 Research and development (R&D) and drug discovery
*2.2.2 Integration and product development
*2.2.3 Manufacturing
*2.2.4 Outbound logistics
*2.2.5 Marketing and sales
*2.2.6 Support services
*2.2.7 Innovation
***3. Market Sizing
**3.1 Market definition
*Exhibit 11: Offerings of vendors included in the market definition
**3.2 Market segment analysis
*Exhibit 12: Market segments
**3.3 Market size 2020
**3.4 Market outlook: Forecast for 2020 - 2025
*3.4.1 Estimating growth rates for emerging and high-growth markets
*3.4.2 Estimating growth rates for mature markets
*Exhibit 13: Global - Market size and forecast 2020 - 2025 ($ million)
*Exhibit 14: Global market: Year-over-year growth 2020 - 2025 (%)
***4. Five Forces Analysis
**4.1 Five Forces Summary
*Exhibit 15: Five forces analysis 2020 & 2025
**4.2 Bargaining power of buyers
*Exhibit 16: Bargaining power of buyers
**4.3 Bargaining power of suppliers
*Exhibit 17: Bargaining power of suppliers
**4.4 Threat of new entrants
*Exhibit 18: Threat of new entrants
**4.5 Threat of substitutes
*Exhibit 19: Threat of substitutes
**4.6 Threat of rivalry
*Exhibit 20: Threat of rivalry
**4.7 Market condition
*Exhibit 21: Market condition - Five forces 2020
***5 Market Segmentation by Product
**5.1 Market segments
*Exhibit 22: Product - Market share 2020-2025 (%)
**5.2 Comparison by Product
*Exhibit 23: Comparison by Product
**5.3 Anticonvulsant drugs - Market size and forecast 2020-2025
*Exhibit 24: Anticonvulsant drugs - Market size and forecast 2020-2025 ($ million)
*Exhibit 25: Anticonvulsant drugs - Year-over-year growth 2020-2025 (%)
**5.4 Antispastic drugs - Market size and forecast 2020-2025
*Exhibit 26: Antispastic drugs - Market size and forecast 2020-2025 ($ million)
*Exhibit 27: Antispastic drugs - Year-over-year growth 2020-2025 (%)
**5.5 Anticholinergic drugs - Market size and forecast 2020-2025
*Exhibit 28: Anticholinergic drugs - Market size and forecast 2020-2025 ($ million)
*Exhibit 29: Anticholinergic drugs - Year-over-year growth 2020-2025 (%)
**5.6 NSAIDs - Market size and forecast 2020-2025
*Exhibit 30: NSAIDs - Market size and forecast 2020-2025 ($ million)
*Exhibit 31: NSAIDs - Year-over-year growth 2020-2025 (%)
**5.7 Antidepressants and others - Market size and forecast 2020-2025
*Exhibit 32: Antidepressants and others - Market size and forecast 2020-2025 ($ million)
*Exhibit 33: Antidepressants and others - Year-over-year growth 2020-2025 (%)
**5.8 Market opportunity by Product
*Exhibit 34: Market opportunity by Product
***6. Customer landscape
**6.1 Overview
*Technavio’s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
*Exhibit 35: ?Customer landscape?
***7. Geographic Landscape
**7.1 Geographic segmentation
*Exhibit 36: Market share by geography 2020-2025 (%)
**7.2 Geographic comparison
*Exhibit 37: Geographic comparison
**7.3 North America - Market size and forecast 2020-2025
*Exhibit 38: North America - Market size and forecast 2020-2025 ($ million)
*Exhibit 39: North America - Year-over-year growth 2020-2025 (%)
**7.4 Asia - Market size and forecast 2020-2025
*Exhibit 40: Asia - Market size and forecast 2020-2025 ($ million)
*Exhibit 41: Asia - Year-over-year growth 2020-2025 (%)
**7.5 Europe - Market size and forecast 2020-2025
*Exhibit 42: Europe - Market size and forecast 2020-2025 ($ million)
*Exhibit 43: Europe - Year-over-year growth 2020-2025 (%)
**7.6 ROW - Market size and forecast 2020-2025
*Exhibit 44: ROW - Market size and forecast 2020-2025 ($ million)
*Exhibit 45: ROW - Year-over-year growth 2020-2025 (%)
**7.7 Key leading countries
*Exhibit 46: Key leading countries
**7.8 Market opportunity by geography
*Exhibit 47: Market opportunity by geography
***8. Drivers, Challenges, and Trends
**8.1 Market drivers
*8.1.1 Rising incidence of cerebral palsy
*8.1.2 Increasing awareness about cerebral palsy
*8.1.3 High patient dependence on medications for cerebral palsy
**8.2 Market challenges
*8.2.1 Complex and multifactorial etiology
*8.2.2 Absence of a curative approach for cerebral palsy
*8.2.3 Disabilities and health problems associated with cerebral palsy
*Exhibit 48: Impact of drivers and challenges
**8.3 Market trends
*8.3.1 Availability of advanced therapeutic modalities for cerebral palsy
*8.3.2 Increasing cerebral palsy research
*8.3.3 Increasing funding by governments for patients with cerebral palsy
***9. Vendor Landscape
**9.1 Overview
*Exhibit 49: Vendor landscape
*The potential for the disruption of the market landscape was moderate in 2020, and its threat is expected to remain unchanged by 2025.
**9.2 Landscape disruption
*Exhibit 50: ?Landscape disruption?
*Exhibit 51: Industry risks
**9.3 Competitive landscape
***10. Vendor Analysis
**10.1 Vendors covered
*Exhibit 52: Vendors covered
**10.2 Market positioning of vendors
*Exhibit 53: ?Market positioning of vendors?
**10.3 Abbott Laboratories
*Exhibit 54: Abbott Laboratories - Overview
*Exhibit 55: Abbott Laboratories - Business segments
*Exhibit 56: Abbott Laboratories - Key offerings
*Exhibit 57: Abbott Laboratories - Segment focus
**10.4 AbbVie Inc.
*Exhibit 58: AbbVie Inc. - Overview
*Exhibit 59: AbbVie Inc. - Business segments
*Exhibit 60: AbbVie Inc. - Key offerings
*Exhibit 61: AbbVie Inc. - Segment focus
**10.5 Acorda Therapeutics Inc.
*Exhibit 62: Acorda Therapeutics Inc. - Overview
*Exhibit 63: Acorda Therapeutics Inc. - Business segments
*Exhibit 64: Acorda Therapeutics Inc. - Key offerings
*Exhibit 65: Acorda Therapeutics Inc. - Segment focus
**10.6 Eli Lilly and Co.
*Exhibit 66: Eli Lilly and Co. - Overview
*Exhibit 67: Eli Lilly and Co. - Business segments
*Exhibit 68: Eli Lilly and Co. - Key offerings
*Exhibit 69: Eli Lilly and Co. - Segment focus
*10.7 F. Hoffmann-La Roche Ltd.
*Exhibit 70: F. Hoffmann-La Roche Ltd. - Overview
*Exhibit 71: F. Hoffmann-La Roche Ltd. - Business segments
*Exhibit 72: F. Hoffmann-La Roche Ltd. - Key offerings
*Exhibit 73: F. Hoffmann-La Roche Ltd. - Segment focus
**10.8 GlaxoSmithKline Plc
*Exhibit 74: GlaxoSmithKline Plc - Overview
*Exhibit 75: GlaxoSmithKline Plc - Business segments
*Exhibit 76: GlaxoSmithKline Plc - Key offerings
*Exhibit 77: GlaxoSmithKline Plc - Segment focus
**10.9 GW Pharmaceuticals Plc
*Exhibit 78: GW Pharmaceuticals Plc - Overview
*Exhibit 79: GW Pharmaceuticals Plc - Business segments
*Exhibit 80: GW Pharmaceuticals Plc - Key offerings
*Exhibit 81: GW Pharmaceuticals Plc - Segment focus
**10.10 Johnson and Johnson Inc.
*Exhibit 82: Johnson and Johnson Inc. - Overview
*Exhibit 83: Johnson and Johnson Inc. - Business segments
*Exhibit 84: Johnson and Johnson Inc. - Key offerings
*Exhibit 85: Johnson and Johnson Inc. - Segment focus
**10.11 Medtronic Plc
*Exhibit 86: Medtronic Plc - Overview
*Exhibit 87: Medtronic Plc - Business segments
*Exhibit 88: Medtronic Plc - Key offerings
*Exhibit 89: Medtronic Plc - Segment focus
**10.12 Pfizer Inc.
*Exhibit 90: Pfizer Inc. - Overview
*Exhibit 91: Pfizer Inc. - Business segments
*Exhibit 92: Pfizer Inc. - Key offerings
*Exhibit 93: Pfizer Inc. - Segment focus
***11. Appendix
**11.1 Scope of the report
*11.1.1 ????Market definition
*11.1.2 ????Objectives
*11.1.3 ????Notes and caveats
**11.2 Currency conversion rates for US$
*Exhibit 94: ?Currency conversion rates for US$?
**11.3 Research Methodology
*Exhibit 95: ?Research Methodology
*Exhibit 96: ??Validation techniques employed for market sizing?
*Exhibit 97: ??Information sources
**11.4 List of abbreviations
*Exhibit 98: List of abbreviations
Get the report (PDF) sent to your email within minutes.
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.
